FDA Action Items For CBD Policy? The List Is Short Due To 'Critical' Data Gaps
Executive Summary
FDA has little in the way of good information it can list on its CBD policy agenda so far, says Principal Deputy Commissioner Amy Abernethy. At recent regulatory conference, she said, "Like it or not, there is a massive human experiment going on right now. There’s CBD in most different product categories and people of many different backgrounds with potential vulnerabilities taking CBD."
You may also be interested in...
FDA Budget Request Includes $5M For CBD Regulation With Pathway Unclear
FDA includes cannabis product regulation in FY 2021 food safety priorities, “key areas where resources have been historically underfunded and for which there are rising public health needs as growing markets outpace increases to Agency resources,” it states in its budget request.
$2m For CBD Policy In FDA Budget, But No Directive On Setting Safe Level
Future Of CBD In Supplements: NDI Notification Looms As Regulatory Path
Recent statement that FDA has not found evidence supporting CBD as GRAS for use in human or animal food potentially points to NDI notifications as the only option manufacturers, marketers and other businesses will have to convince agency about safety for CBD and other hemp-derived substances used in dietary supplements.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests:
